Innovative Non-Surgical Treatment for TMJ Defects

USA: Regenative Labs, a human cell, tissue, and cellular and tissue-based product (HCT/P) manufacturer, has announced a case study that showcases new advancements in care. This study highlights the innovative use of Regenative’s Wharton’s Jelly allografts in the treatment of Temporomandibular Joint (TMJ) defects. 

The case study, titled “Single-Center Retrospective Study of Flowable Umbilical Cord Tissue Allograft Application in Temporomandibular Joint Defects: An Investigative Study,” was published in collaboration with Walsh Medical Media.

Study Reveals Bidirectional Link Between TMJD and Depression/Anxiety

Redefining TMJ Treatment

Board-certified sleep medicine and craniofacial pain specialists, Dr. Ryan Robinson and NP Rachel Reynolds from The Pain and Sleep Therapy Center, have conducted an exceptional case series. This study explores the application of Wharton’s Jelly, a connective tissue derived from the umbilical cord, for treating structural tissue defects in the temporomandibular joint. This novel approach sets a precedent for non-surgical allograft application.

Patients with chronic and severe TMJ degeneration who had previously failed standard-of-care practices experienced remarkable improvements. Following a single application of Regenative’s Wharton’s Jelly allograft, patients reported an average pain reduction of 75% after 90 days. This innovative approach offers a more convenient and less invasive alternative to surgical treatments.

Addressing the TMJ Challenge

Temporomandibular joint disorders affect nearly 10 million patients in the United States annually, leading to symptoms such as joint pain, limited mouth opening, joint clicking, and referred pain. Traditional treatments, including surgery, often result in high out-of-pocket costs for patients, with treatment expenses ranging from $5,000 to $50,000. Regenative’s approach aims to provide a more cost-effective, non-surgical alternative.

NP Rachel Reynolds, one of the study’s lead researchers, emphasizes the need for broader, less invasive treatment options for TMJ patients. She hopes that the study’s promising outcomes will encourage physicians to adopt more conservative treatments and provide patients with additional options.

Orofacial Symptoms Are Potential Indicators of Malignancy, Says Study

Regenative Labs CEO, Tyler Barrett, is committed to advancing the field of regenerative medicine. He highlights the significance of gathering data and the potential of non-surgical alternatives. Regenative has been accumulating data from physicians nationwide who track patient outcomes following the application of Regenative’s products. Barrett and his team are eager to explore new applications and are actively seeking the participation of physicians in further studies.

About Regenative Labs

Regenative Labs specialises in regenerative medicine products that address the root causes of patient conditions. The company collaborates with scientists, physicians, hospitals, and surgery centres to monitor and improve patient progress and outcomes continually. Regenative Labs adheres to FDA guidelines for minimal manipulation for homologous use and complies with AATB and FDA standards. Their goal is to offer non-addictive, non-invasive options for patients.

Read the Case Study: Single-Center Retrospective Study of Flowable Umbilical Cord Tissue Allograft Application in Temporomandibular Joint Defects: An Investigative Study